期刊文献+

化疗对晚期肺癌患者凝血、纤溶系统影响的临床研究 被引量:11

Influence of chemotherapy on coagulation and fibrinolysis system in patients with advanced lung cancer
暂未订购
导出
摘要 目的探讨晚期肺癌患者化疗前后凝血指标的变化及意义。方法对50例晚期肺癌患者(肺癌组)化疗前后血浆凝血酶原时间(PT)、部分凝血活酶时间(APTT)、凝血酶时间(TT)、血纤维蛋白原量(Fbg)及D-二聚体(D-D)水平进行检测,并与30例健康成人(对照组)所测结果进行对比分析。结果肺癌组APTT、TT均较对照组显著缩短(P<0.01),血浆Fbg、D-D水平均明显高于对照组(P<0.01)。肺癌组化疗后较化疗前PT显著延长,APTT、TT显著缩短,Fbg及D-D水平显著升高(P<0.05或P<0.01)。结论化疗加剧晚期肺癌患者机体凝血因子的释放以及纤溶功能受抑状态,使凝血功能异常。 Objective To evaluate the variation and meaning of coagulation index before and after chemotherapy in patients with advanced lung cancer. Methods The plasma levels of pro- thrombin time (PT), fibrinogen (Fbg), activated partial thromboplastin time (APTT), thrombin time (TT) and D-dimer (D-D) were tested in 50 patients with advanced lung cancer (lung cancer group) and compared with 30 healthy adults (control group). Results Compared with the control group, the mean values of APTT, TT in lung cancer group were significantly shorter, and the Fbg, 13-13 were significantly higher (P 〈0.01). Compared with pre-chemotherapy, the PT in lung can- cer group post-chemotherapy was longer, the APTT, TT were shorter, and the Fbg, D-D were higher (P 〈 0.05 or P 〈 0.01 ). Conclusion Chemotherapy may exacerbate the release of coagula- tion factors and inhibition state of fibrinolysis system, which results in abnormal coagulation in ad- vanced lung cancer.
出处 《实用临床医药杂志》 CAS 2012年第19期46-48,共3页 Journal of Clinical Medicine in Practice
关键词 肺肿瘤 化疗 凝血指标 纤溶功能 lung cancer chemotherapy coagulayion index
  • 相关文献

参考文献13

二级参考文献67

  • 1申洪,陈清.标准化预告值概念及标化方法探讨[J].中华流行病学杂志,1994,15(6):360-362. 被引量:10
  • 2石建霞,顾健.凝血酶与肿瘤的血管新生[J].中国实验血液学杂志,2006,14(1):197-200. 被引量:11
  • 3李晓娜,丁进芳,王凤兰,钟兰君,李芳文,边玉军,张兴旺.凝血酶激活的纤溶抑制物与2型糖尿病微量白蛋白尿症的关系[J].中华检验医学杂志,2006,29(7):620-621. 被引量:2
  • 4陆慰萱,王辰.肺循环病学[M].北京:人民卫生出版社,2007:657-661.
  • 5孟宇宏,虞积耀,陆应麟.凝血酶与肿瘤转移[J].中国实验血液学杂志,2007,15(3):671-674. 被引量:11
  • 6Zhong W, Zhao J, Zhang XT, et al. The efficacy and safety of pemetrexed as mono3 for Chinese patients with advanced non-small cell lung cancer[J]. Zhonghua Nei Ke Za Zhi, 2010, 49(8): 671-4.
  • 7Fuld AD, Dragnev KH, Rigas JR. Pemetrexed in advanced non-small-cell lung cancer [J]. Expert Opin Pharmacother, 2010, 11(8): 1387-402.
  • 8Zhang C, Elkahlotm AG, Robertson M, et al. Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer and Confers Chemotherapeutic Resistance [J]. PLoS One, 2011, 6(8): e23849.
  • 9Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset[J]. Mod Pathol, 2009, 22(4): 508-15.
  • 10Hsu DS, Acharya CR, Balakumaran BS, et al. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer [J]. Proc Natl Acad Sci USA, 2009, 106(13): 5312-7.

共引文献44

同被引文献117

引证文献11

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部